CIDP Reinforces its Commitment to the Personal Care & Beauty Industry


Alternativ











CRO Obtains ISO-Certification and Rolls Out Blue Light Study Protocol

Mauritius, 21 April 2017

After a successful showing at the recent in-cosmetics Global event, CIDP, Centre International de Développement Pharmaceutique, a Mauritius-based private and independent Contract Research Organisation (CRO), today announces company updates and upcoming activities for the personal care sector.
 
Earlier this month, at the in-cosmetics Global show in London, CIDP featured its full suite of services and presented an innovative study protocol for substantiating anti-pollution claims made on cosmetic products. The company’s showcase proved to be right on-trend as ‘anti-pollution’ was a key buzzword for many industry professionals at the trade event.
 
Mr Jean-Louis Roule, CEO of CIDP, said, “We’ve received a lot of interest from cosmetic manufacturers for support in claims substantiation, as well as for our unique ingredients extracted from botany that’s native to Mauritius. Our team will continue these conversations to see how CIDP can assist in creating even more innovative products that consumers seek and love.



New Milestone: All Centres Now ISO-Certified
As a leader in the biotech research field, CIDP is committed to service excellence through its Quality Management processes. Across its five centres in Mauritius, Brazil, India, Romania, and Singapore, CIDP has always ensured the implementation of stringent quality requirements that are compliant with international standards.
 
The company’s high regard for service delivery has given it a reputation as a trusted partner that delivers consistent and effective results in an efficient manner. Following the completion of audits carried out by independent certification bodies, all of CIDP’s centres now possess ISO 9001:2015 certification.
 
Next Chapter: New Methodologies for Blue Light Claims Substantiation
Looking ahead, CIDP is committed to continue developing innovative clinical study designs and improving them to suit its customers’ needs. The cosmetics and beauty industry can look forward to another new study protocol from CIDP, which assesses the photoprotective effect of products against blue light-induced pigmentation.
 
The company will next be presenting at another established industry event – the 14th International Sun Protection Conference, which will be held from 6 – 7 June 2017 at the Royal College of General Practitioners, 30 Euston Square, in London. Addressing new concepts in sun exposure and protection, Jessen Curpen, Biophysics Manager and Head of Clinical Study Design at CIDP, will speak about the cutaneous pigmentation effect of blue light.
 
For decades, the personal care industry has tested sunscreens for their efficacy in protecting the skin against UVA and UVB components of sunlight. However, recent research has shown that blue light (400 – 470 nm) causes significant cutaneous pigmentation effects. In his presentation, Curpen discusses standard UVA/UVB tests and focuses on possible new methodologies that can be set in place to evaluate the photoprotective effect of products against blue light-induced pigmentation.
 
Protection from blue light exposure is a relatively new concept that consumers are starting to be more aware about,” Jessen Curpen explained. “I’m excited to share more about our findings, what we’ve developed, and how we can help the industry.


About Centre International de Développement Pharmaceutique (CIDP)
Based in Mauritius, CIDP, Centre International de Développement Pharmaceutique is a private and independent Contract Research Organisation (CRO) that conducts high-performing research and clinical activities for cosmetics, pharmaceutical, medical device, and nutrition industries. The group serves clients both as a service provider upstream through Research and Preclinical activities, and downstream through Regulatory Affairs, Biostatistics & Data Management, and Clinical Research.
 
Comprising a strong team of highly qualified and experienced professionals, such as doctors, pharmacists, biologists and chemists, clinical research/trial assistants and managers, biostatisticians, and data managers, CIPD’s scientific know-how covers various aspects of drug discovery, and services offered include the evaluation of ingredients, raw materials, as well as drugs or cosmetics products.
 
The geographical locations of CIDP’s centres – in Mauritius, Brazil, India, Romania, and Singapore – enable the company the access to a wide panel of patients. This allows the group to undertake multi-centric trials with a rapid recruitment process in a secured and adapted environment. Recognised for its expertise, CIDP works with the leaders of the cosmetics and pharmaceutical industry.
 
CIDP forms part of the IBL group. IBL is ranked among the 16 most dynamic and fast growing companies in Africa, according to the World Economic Forum in 2016. Ranked number 1 in the TOP 100 Mauritian companies and number 3 in the Indian Ocean, IBL invests in Life sciences through its subsidiary: IBL Life. Its ambition is to become the essential starting point in this growing sector.
 
For more information, please visit www.cidp-cro.com.

« back